Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Cardiology/Vascular Diseases | Hematology
 Disease Category: Thrombosis
Location: United States, ND

Trial Information

Prevention of venous thromboembolism (VTE) in cancer patients at high risk for VTE and who are undergoing chemotherapy

To compare the efficacy of once daily injections in the prevention of venous thromboembolism (VTE) in cancer patients at high risk for VTE and who are undergoing chemotherapy

Patient Inclusion Criteria:

  • Cancer patients with metastatic or locally advance solid tumor of the lung, pancreas, stomach, colon/rectum, bladder or ovary, planned to start a new course of chemotherapy with a minimum intent of 3 months therapy

Patient Exclusion Criteria:

  • Life expectancy of less than 3 months, any major surgery within the last 4 weeks or planned during the study treatment period, any treatment with other anti-thrombotic agents within 2 weeks prior to randomization

Dr. Tom Davis, Director of Business Development
Legacy Pharma Research
601 N. 5th St.
Bismarck, ND 58501
Phone: 701-751-1128
Fax: 701-751-1131
Email: tdavis.legacy@midconetwork.com

View Map

Research Center Information: Legacy Pharma Research

If you would like to learn more about participating in this study, please send an email message using the form below.

Name:
Address:
City:
State:
Country:
Phone:
Email:  
Message:
 

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.